A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 170 participants.

Also called NCT07668336

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 170 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07668336
  • EU CT 2025-524811-35-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Belgium, Brazil, India, Italy, Japan, Mexico, South Korea, Spain, Taiwan, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07668336. Randomized; no masking; primary purpose treatment. Start 2026-07-08 (actual); primary completion 2030-03 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
Acronym
ACHIEVE-PEDS
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Orforglipron
Intervention (Drug)
Dulaglutide
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct07668336
Content hash
dccb2c56f320e109c7dede46ac05716d1e7ea0f7c3e8066d7190290a3df47c5b